<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00147290</url>
  </required_header>
  <id_info>
    <org_study_id>400ACRT</org_study_id>
    <nct_id>NCT00147290</nct_id>
  </id_info>
  <brief_title>ADVANCE CRT - D: Antitachycardia Pacing (ATP) Delivery for Painless Implantable Cardioverter Defibrillator (ICD) Therapy</brief_title>
  <acronym>ADVANCE-CRTD</acronym>
  <official_title>ADVANCE CRT - D: ATP Delivery for Painless ICD Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Bakken Research Center</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Bakken Research Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the efficacy of RV and BiV ATP for the termination of ventricular arrhythmias in
      patients who are candidates to a cardiac resynchronisation therapy (CRT) and have a Class I
      or IIA indication for ICD implantation.

      The hypothesis of delivering ATP from different sites (RV or BIV) has never been evaluated in
      a prospective, controlled and randomized study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Main objective: Compare efficacy of ATP therapy (Burst, 8 pulses, 88 %, 1 sequence) to
      terminate all types of ventricular tachycardia (all VTs (FVT+VT)) when delivered in the right
      ventricle (RV) only versus both ventricles (BiV) resulting in a 10 % difference in favour of
      BIV ATP

      Secondary objectives:

        -  Compare efficacy of the first BiV and RV ATP (Burst, 8 pulses, 88 %) to terminate fast
           ventricular tachycardia (FVT)

        -  Compare efficacy of the first BiV and RV ATP (Burst, 8 pulses, 88 %) to terminate slow
           ventricular tachycardia (slow VT)

        -  Compare efficacy of BiV and RV ATP (all ATP therapies) to terminate slow ventricular
           tachycardia (slow VT)

        -  Determine the rate of both FVT and VT episodes which are accelerated or degenerates into
           VF
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2004</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">April 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of Anti Tachycardia Pacing (ATP) Therapy (Burst, 8 Pulses, 88 %, 1 Sequence) to Terminate All Types of Ventricular Tachycardia.</measure>
    <time_frame>one year</time_frame>
    <description>Termination of Ventricular Tachycardia is calculated as percentage of successfully terminated episodes, adjusted for multiple events with GEE method. This technique yields an average therapy efficacy and 95% CI that is based on number of patients, number of episodes per patient, and magnitude of the correlation between responses within patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare Efficacy of the First BiV and RV ATP to Terminate FVT</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare Efficacy of the First BiV and RV ATP to Terminate Slow VT</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare Efficacy of BiV and RV ATP (All ATP Therapies) to Terminate Slow VT</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the Rate of Both FVT and VT Episodes Which Are Accelerated or Degenerates Into VF</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">526</enrollment>
  <condition>Tachycardia, Ventricular</condition>
  <condition>Ventricular Fibrillation</condition>
  <arm_group>
    <arm_group_label>BiV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ATP therapies are delivered in both the ventricles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ATP delivered only in the right ventricle</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Implantable Cardiac Defibrillator</intervention_name>
    <description>Implantable cardiac defibrillator with programmable Fast Ventricular tachycardia detection (FVT) window</description>
    <arm_group_label>BiV</arm_group_label>
    <arm_group_label>RV</arm_group_label>
    <other_name>ICD</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  CRT + ICD indications (Class I-IIA) according to the guidelines

          -  Patients have been implanted with a Medtronic Marquis Family ICD capable of RV-ATP or
             BIV-ATP

          -  Patients in chronic AF who undergo a complete AV ablation and that the complete AV
             block is confirmed at PHD

        Exclusion Criteria:

          -  Patient's life expectancy less than 1 year due to a non cardiac chronic disease

          -  Patient on heart transplant list which is expected in &lt; 1 year

          -  Patient's age less than 18 years

          -  Replacements and upgrades

          -  Epicardial lead

          -  Mechanical tricuspid valve

          -  Ventricular Tachyarrhythmias associated with reversible causes

          -  Unwillingness or inability to provide written informed consent

          -  Enrollment in, or intention to participate in, another clinical study during the
             course of this study

          -  Inaccessibility for follow-up at the study center
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maurizio Gasparini, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istituto Clinico Humanitas Mirasole SpA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mario Bocchiardo, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ospedale Civile di Asti</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antonio Curnis, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Spedali Civili di Brescia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rafael Peinado, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>La Paz Madrid</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philippe Mabo, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rennes University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas Lavergne, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>E. H. Pompidou - Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Frederic Anselme, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Rouen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joerg Schwab, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Clinic - Bonn</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medtronic Italia SpA</name>
      <address>
        <city>Sesto San Giovanni</city>
        <state>Milan</state>
        <zip>20099</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Schwab JO, Gasparini M, Anselme F, Mabo P, Peinado R, Lavergne T, Bocchiardo M, Mascioli G, Passardi M, Mainardis M. Right ventricular versus biventricular antitachycardia pacing in the termination of ventricular tachyarrhythmia in patients receiving cardiac resynchronization therapy: the ADVANCE CRT-D trial. J Cardiovasc Electrophysiol. 2006 May;17(5):504-7.</citation>
    <PMID>16684023</PMID>
  </reference>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 6, 2005</study_first_submitted>
  <study_first_submitted_qc>September 6, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2005</study_first_posted>
  <results_first_submitted>November 20, 2008</results_first_submitted>
  <results_first_submitted_qc>April 21, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 10, 2009</results_first_posted>
  <last_update_submitted>August 12, 2015</last_update_submitted>
  <last_update_submitted_qc>August 12, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 13, 2015</last_update_posted>
  <responsible_party>
    <name_title>Elisabetta Santi</name_title>
    <organization>Medtronic</organization>
  </responsible_party>
  <keyword>ATP</keyword>
  <keyword>Tachycardia</keyword>
  <keyword>CRT-D</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Ventricular Fibrillation</mesh_term>
    <mesh_term>Tachycardia, Ventricular</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Right Ventricle (RV)</title>
          <description>Anti Tachyarrhythmia Pacing (ATP) therapies are delivered in the right ventricle</description>
        </group>
        <group group_id="P2">
          <title>Biventricular (BiV)</title>
          <description>Anti Tachyarrhythmia Pacing (ATP) are delivered in both ventricles</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="266"/>
                <participants group_id="P2" count="260"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="266"/>
                <participants group_id="P2" count="260"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Right Ventricle (RV)</title>
          <description>Anti Tachyarrhythmia Pacing (ATP) therapies are delivered in the right ventricle</description>
        </group>
        <group group_id="B2">
          <title>Biventricular (BiV)</title>
          <description>Anti Tachyarrhythmia Pacing (ATP) are delivered in both ventricles</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="266"/>
            <count group_id="B2" value="260"/>
            <count group_id="B3" value="526"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="94"/>
                    <measurement group_id="B2" value="95"/>
                    <measurement group_id="B3" value="189"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="172"/>
                    <measurement group_id="B2" value="165"/>
                    <measurement group_id="B3" value="337"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.6" spread="10.2"/>
                    <measurement group_id="B2" value="66.8" spread="9.5"/>
                    <measurement group_id="B3" value="66.7" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="231"/>
                    <measurement group_id="B2" value="218"/>
                    <measurement group_id="B3" value="449"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="122"/>
                    <measurement group_id="B2" value="127"/>
                    <measurement group_id="B3" value="249"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Israel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Portugal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Efficacy of Anti Tachycardia Pacing (ATP) Therapy (Burst, 8 Pulses, 88 %, 1 Sequence) to Terminate All Types of Ventricular Tachycardia.</title>
        <description>Termination of Ventricular Tachycardia is calculated as percentage of successfully terminated episodes, adjusted for multiple events with GEE method. This technique yields an average therapy efficacy and 95% CI that is based on number of patients, number of episodes per patient, and magnitude of the correlation between responses within patients.</description>
        <time_frame>one year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Right Ventricle (RV)</title>
            <description>Anti Tachyarrhythmia Pacing (ATP) therapies are delivered in the right ventricle</description>
          </group>
          <group group_id="O2">
            <title>Biventricular (BiV)</title>
            <description>Anti Tachyarrhythmia Pacing (ATP) are delivered in both ventricles</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy of Anti Tachycardia Pacing (ATP) Therapy (Burst, 8 Pulses, 88 %, 1 Sequence) to Terminate All Types of Ventricular Tachycardia.</title>
          <description>Termination of Ventricular Tachycardia is calculated as percentage of successfully terminated episodes, adjusted for multiple events with GEE method. This technique yields an average therapy efficacy and 95% CI that is based on number of patients, number of episodes per patient, and magnitude of the correlation between responses within patients.</description>
          <units>Percent of VT episodes terminated</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="260"/>
                <count group_id="O2" value="266"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.7"/>
                    <measurement group_id="O2" value="68.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Compare Efficacy of the First BiV and RV ATP to Terminate FVT</title>
        <time_frame>one year</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Compare Efficacy of the First BiV and RV ATP to Terminate Slow VT</title>
        <time_frame>one year</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Compare Efficacy of BiV and RV ATP (All ATP Therapies) to Terminate Slow VT</title>
        <time_frame>one year</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Determine the Rate of Both FVT and VT Episodes Which Are Accelerated or Degenerates Into VF</title>
        <time_frame>one year</time_frame>
      </outcome>
    </outcome_list>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Elisabetta Santi</name_or_title>
      <organization>Medtronic</organization>
      <phone>003906328141</phone>
      <email>elisabetta.santi@medtronic.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

